Commentary Open Access
Volume 2 | Issue 3 | DOI: https://doi.org/10.33696/cancerimmunol.2.017
Purinergic System and Cervical Cancer: Perspectives
Marta Schmidt Pfaffenzeller1, Maria Luiza Mukai Franciosi1, Adriana Fuganti Wagner1, Andreia Machado Cardoso1,*
- 1Medicine Course, Campus Chapecó, Federal University of Fronteira Sul, Chapecó, SC, Brazil
Corresponding Author
Andreia Machado Cardoso, andreia.cardoso@uffs.edu.br
Received Date: April 02, 2020
Accepted Date: June 02, 2020
Pfaffenzeller MS, Franciosi MLM, Wagner AF, Cardoso AM. Purinergic System and Cervical Cancer: Perspectives. J Cancer Immunol. 2(3): 62-65.
Copyright: © 2016 2020 Pfaffenzeller MS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Development of HPV 16/18 E6 Oncoprotein Paperbased Nanokit for Enhanced Detection of HPV 16/18 E6 Oncoprotein in Cervical Cancer Screening
According to global cancer statistics GLOBOCAN, carcinoma of cervix is ranked as the fourth most common malignancy among women worldwide with an estimation of 570,000 cases and 311,000 deaths in 2018. It is the second most common female malignancy in Lowand- Middle Income Countries (LMICs). In Kenya, the prevalence is 25 cases per 100,000 women. Approximately 75% cases of cervical cancer are caused by persistent infections of the cervical mucosal epithelium with carcinogenic types of human papillomaviruses (HPVs) mainly 16 and 18.
Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery in Stage 1B2 Cervical Cancer
In 2020 we published a series of 18 patients who underwent neoadjuvant chemotherapy (NACT) and vaginal radical trachelectomy (VRT) as a fertility sparing alternative in stage 1B2 cervical cancer.
Purinergic System and Cervical Cancer: Perspectives
We have recently published an article entitled “Purinergic signaling and tumor microenvironment in cervical Cancer”. In this paper, we reviewed the last studies about purinergic signaling and cervical cancer, highlighting the intrinsic factors related to the inflammatory process, such as extracellular nucleotides and adenosine - components of the purinergic system.
Cervical Cancer Prevalence in sub-Saharan Africa and HPV Vaccination Policy: A Public Health Grand Challenge?
“Women are not dying because of diseases we cannot treat. They are dying because societies have yet to make the decision that their lives are worth saving.”
A novel therapeutic strategy for antifibrotic based on a new gene NS5ATP9
In this article, we introduced a screening of anti-fibrotic drugs focused on new genes. More precisely, we screened and cloned 127 new genes, reporting on a potential target gene and two promising drugs for fibrosis. Among 127 genes, hepatitis C virus nonstructural protein 5A transactivated protein 9 (NS5ATP9), which expression is significantly upregulated by tenofovir disoproxil fumarate (TDF)/tenofovir alafenamide fumarate (TAF), suppresses hepatic stellate cells (HSCs) and HFL1 cells (lung fibroblasts) activation.